UC Irvine

UC Irvine Previously Published Works

Title

Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia.

Permalink

<https://escholarship.org/uc/item/5k28c476>

Journal

Neuropharmacology, 50(3)

ISSN

0028-3908

Authors

Suplita, Richard L
Gutierrez, Tannia
Fegley, Darren
et al.

Publication Date

2006-03-01

DOI

10.1016/j.neuropharm.2005.10.007

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia

Richard L. Suplita II^a, Tannia Gutierrez^a, Darren Fegley^b,
Daniele Piomelli^b, Andrea G. Hohmann^{a,*}

^a Neuroscience and Behavior Program, Department of Psychology, University of Georgia, Baldwin Street, Athens, GA 30602-3013, USA

^b Department of Pharmacology and Center for Drug Discovery, University of California, Irvine, CA 92697-4260, USA

Received 10 August 2005; received in revised form 10 October 2005; accepted 11 October 2005

Abstract

Recent work in our laboratories has demonstrated that an opioid-independent form of stress-induced analgesia (SIA) is mediated by endogenous cannabinoids [Hohmann et al., 2005. *Nature* 435, 1108]. Non-opioid SIA, induced by a 3-min continuous foot shock, is characterized by the mobilization of two endocannabinoid lipids—2-arachidonoylglycerol (2-AG) and anandamide—in the midbrain periaqueductal gray (PAG). The present studies were conducted to examine the contributions of spinal endocannabinoids to nonopioid SIA. Time-dependent increases in levels of 2-AG, but not anandamide, were observed in lumbar spinal cord extracts derived from shocked relative to non-shocked rats. Notably, 2-AG accumulation was of smaller magnitude than that observed previously in the dorsal midbrain following foot shock. 2-AG is preferentially degraded by monoacylglycerol lipase (MGL), whereas anandamide is hydrolyzed primarily by fatty-acid amide hydrolase (FAAH). This metabolic segregation enabled us to manipulate endocannabinoid tone at the spinal level to further evaluate the roles of 2-AG and anandamide in nonopioid SIA. Intrathecal administration of the competitive CB₁ antagonist SR141716A (rimonabant) failed to suppress nonopioid SIA, suggesting that supraspinal rather than spinal CB₁ receptor activation plays a pivotal role in endocannabinoid-mediated SIA. By contrast, spinal inhibition of MGL using URB602, which selectively inhibits 2-AG hydrolysis in the PAG, enhanced SIA through a CB₁-selective mechanism. Spinal inhibition of FAAH, with either URB597 or arachidonoyl serotonin (AA-5-HT), also enhanced SIA through a CB₁-mediated mechanism, presumably by increasing accumulation of tonically released anandamide. Our results suggest that endocannabinoids in the spinal cord regulate, but do not mediate, nonopioid SIA.

© 2005 Elsevier Ltd. All rights reserved.

Keywords: Anandamide; Endocannabinoid; 2-Arachidonoylglycerol; Periaqueductal gray; Rostral ventromedial medulla; Stress antinociception; Fatty-acid amide hydrolase; Monoacylglycerol lipase; Dorsal horn

1. Introduction

Stress-induced analgesia (SIA) is mediated by the activation of endogenous pain inhibitory systems. Both opioid-dependent and opioid-independent forms of SIA have been identified (see Akil et al., 1986 for review). These mechanisms are differentially activated according to stressor parameters and duration (Lewis et al., 1980a,b). SIA elicited by

intermittent foot shock is blocked by opioid antagonists (Lewis et al., 1980a), whereas SIA elicited by continuous foot shock (3 min) is blocked by cannabinoid antagonists (Hohmann et al., 2005). We recently demonstrated that this nonopioid form of SIA is mediated by mobilization of two endocannabinoids, 2-arachidonoylglycerol (2-AG) and anandamide, in the dorsal midbrain (Hohmann et al., 2005).

Opioid and nonopioid SIA share similar neuroanatomical substrates. For example, opioid and cannabinoid receptors populate brain regions regulating nociceptive responding, such as the periaqueductal gray (PAG) (Martin et al., 1995; Lichtman et al., 1996) and the raphe nuclei of the medulla

* Corresponding author. Tel.: +1 706 542 2252; fax: +1 706 542 3275.
E-mail address: ahohmann@uga.edu (A.G. Hohmann).

(Herkenham et al., 1991). Like opioids, cannabinoids modulate distinct circuits within the midbrain PAG (Vaughan et al., 2000) and the brainstem rostral ventromedial medulla (RVM) (Meng et al., 1998). The competitive CB₁ antagonist/inverse agonist SR141716A (rimonabant) microinjected into either the dorsolateral PAG (dPAG) (Hohmann et al., 2005) or RVM (Suplita et al., *in press*) also attenuates SIA. By contrast, inhibition of endocannabinoid hydrolysis at these sites enhances SIA (Hohmann et al., 2005; Suplita et al., *in press*). These data support the existence of supraspinal sites of endocannabinoid analgesic action.

Cannabinoids produce antinociception through spinal as well as supraspinal mechanisms (for review, see Hohmann and Suplita, 2004). The antinociceptive (Lichtman and Martin, 1991) and electrophysiological (Hohmann et al., 1999c) effects of cannabinoids are attenuated following spinal transection. Nonetheless, a long-lasting residual antinociception remains in spinally transected mice (Smith and Martin, 1992), suggesting the existence of spinal sites of endocannabinoid analgesic action. These data are consistent with the presence of CB₁ receptors in the spinal dorsal horn (Tsou et al., 1998a; Hohmann et al., 1999a; Farquhar-Smith et al., 2000). Intrathecally-administered cannabinoids also produce antinociception (Yaksh, 1981; Smith and Martin, 1992; Welch and Stevens, 1992; Welch et al., 1995; Martin et al., 1999) and suppress noxious stimulus-evoked neuronal activity in spinal nociceptive neurons (Hohmann et al., 1998, 1999b; Drew et al., 2000; Kelly and Chapman, 2001), suggesting a functional role for spinal cannabinoid receptors in modulating nociceptive processing. Intrathecal administration of either rimonabant or CB₁ antisense oligonucleotides also elicits hyperalgesia (Richardson et al., 1998), suggesting that endocannabinoids may act tonically to suppress nociceptive responding. However, a physiological role for endocannabinoids at the spinal level has not been identified.

Both 2-AG and anandamide fully qualify as endocannabinoids (see Piomelli, 2003 for review). These lipids are synthesized and released on-demand, activate cannabinoid CB₁ receptors with high affinity, and are metabolized *in vivo* by distinct hydrolytic pathways. Within the CNS, 2-AG is present in quantities 170–1000 times greater than those of anandamide (Sugiura et al., 1995; Stella et al., 1997). 2-AG serves as a full agonist at CB₁ and CB₂ (Sugiura et al., 1999, 2000; Gonsiorek et al., 2000; Savinainen et al., 2001), whereas anandamide is less efficacious (Sugiura et al., 1995; Stella et al., 1997; Savinainen et al., 2001).

2-AG is preferentially degraded by monoacylglycerol lipase (MGL) (Dinh et al., 2002a,b, 2004), whereas anandamide is preferentially hydrolyzed by fatty-acid amide hydrolase (FAAH) (Cravatt et al., 1996). Mutant mice lacking the FAAH gene (FAAH^{−/−}) are impaired in their ability to degrade anandamide and display reduced pain sensation that is reversed by the CB₁ antagonist rimonabant (Cravatt et al., 1996; Lichtman et al., 2002). Immunocytochemical studies have revealed a heterogeneous distribution of FAAH throughout the brain and moderate staining of FAAH-positive cells in the superficial dorsal horn of the spinal cord (Tsou et al.,

1998b). In brain, the regional distribution of MGL partially overlaps with that of the CB₁ receptor (Dinh et al., 2002a,b). Inhibition of MGL in the midbrain PAG increases 2-AG accumulation and enhances SIA in a CB₁-dependent manner (Hohmann et al., 2005), supporting a physiological role for 2-AG in neural signaling. Thus, the anatomical distributions of FAAH and MGL are consistent with a role for these enzymes in terminating the activity of endocannabinoids.

The present studies were conducted to investigate the contribution of endocannabinoids acting at spinal CB₁ receptors to nonopioid SIA. We used high-performance liquid chromatography/mass spectrometry (LC/MS) to examine the contribution of 2-AG and anandamide at the spinal level to SIA. We examined the time-course of changes in endocannabinoid levels in the lumbar spinal cord of control rats and rats subjected to foot shock stress. Moreover, we used selective inhibitors of MGL (URB602; Hohmann et al., 2005) and FAAH (URB597; Kathuria et al., 2003) to further elucidate the roles of these endocannabinoids in SIA. We additionally evaluated effects of intrathecal administration of arachidonoylserotonin (AA-5-HT; Bisogno et al., 1998), a FAAH inhibitor that is inactive at phospholipase A₂ and CB₁ receptors, on SIA. We hypothesized that intrathecal administration of these inhibitors would potentiate nonopioid SIA via a CB₁ mechanism. Preliminary results have been reported (Hohmann et al., 2005).

2. Methods

2.1. Subjects

One hundred forty-four adult male Sprague–Dawley rats (320–370 g) were used in these experiments. All procedures were approved by the University of Georgia Animal Care and Use Committee and followed the guidelines for the treatment of animals of the International Association for the Study of Pain (Zimmermann, 1983).

2.2. Drugs

The CB₁ antagonist/inverse agonist SR141716A (rimonabant) was a gift from NIDA. The fatty acid amide hydrolase (FAAH) inhibitors URB597 and arachidonoyl serotonin (AA-5-HT) were purchased from Cayman (Ann Arbor, MI). URB602 (biphenyl-3-yl carbamic acid cyclohexyl ester) was synthesized by reacting diimidazole-1-ylmethanone with biphenyl-3-yl amine in acetonitrile in the presence of 4-dimethylaminopyridine and subsequently with cyclohexanol as described previously (Hohmann et al., 2005).

2.3. Lipid extractions and LC/MS analyses

For *ex vivo* experiments, we habituated otherwise naive rats to the guillotine for at least 7 days prior to the experiment and killed them either without exposure to or at various times (2, 7, 15, and 25 min) after foot shock (0.9 mA for 3 min; *n* = 10 per group). The lumbar spinal cords were quickly dissected and stored frozen (−80 °C) until lipid extraction. Lipids were extracted in methanol/chloroform/water (1:2:0.25), and the organic phase was recovered, evaporated to dryness, reconstituted in chloroform/methanol (1:3, 80 µl) and subjected to LC/MS analysis as described previously (Giuffrida et al., 1999; Hohmann et al., 2005).

2.4. Surgical procedures

Rats were anesthetized with a mixture of sodium pentobarbital and ketamine. Intrathecal catheters were constructed from PE10 tubing (Yaksh and

Rudy, 1976). Catheters were implanted through an incision in the atlanto-occipital membrane to a depth of 8.5 cm. The catheter tip extended just rostral to the lumbar enlargement. Catheters were fixed to the skull with a stainless steel screw and dental acrylic. Animals were allowed to recover five to seven days prior to testing.

2.5. Behavioral testing

SIA was quantified behaviorally using the tail-flick test (D'Amour and Smith, 1941). After establishing stable baseline responses to thermal stimulation of the tail (model 33A tail-flick unit, IITC Inc., Woodland Hills, CA), rats received a single intrathecal injection of rimonabant (2 or 20 nmol), URB602 (1 nmol), URB597 (1 nmol), AA-5-HT (1 or 200 nmol) or DMSO vehicle. Drugs were injected in a volume of 10 μ l followed by an equivalent volume of saline to flush the catheter. Tail-flick latencies were assessed three times at 2-min intervals immediately following drug administration to assess changes in tail-flick latency induced by the injection itself. Rats were subsequently subjected to continuous foot shock (0.9 mA for 3 min; Hohmann et al., 2005). Tail-flick latencies were reassessed at 2-min intervals for 60 min and averaged for each subject in two trial blocks. A 10-s cut-off latency was employed to prevent tissue damage. The region of the tail subjected to thermal stimulation was slightly varied across trials to eliminate sensitization. In previous studies we showed that tail-flick latencies remain stable throughout the entire observation interval in the absence of the stressor (Hohmann et al., 2005). Following sacrifice, catheter placement was verified by injection of fast green dye followed by dissection.

2.6. Statistical analyses

Time course data were analyzed using repeated measures analysis of variance (ANOVA). Post hoc comparisons were performed using Fisher's Protected Least-Squares Difference (LSD) test to correct for inflated alpha error, with $P < 0.05$ considered significant. Pearson's correlation coefficients were calculated to assess the relationship between spinal endocannabinoid mobilization and SIA.

3. Results

3.1. Effects of foot shock stress on endocannabinoid levels

To determine whether endocannabinoid release participates in non-opioid SIA, we analyzed 2-AG and anandamide levels in the lumbar spinal cords of rats killed before (non-shock) or at various times after foot shock using LC/MS. Example chromatograms show the coelution of endogenous 2-AG and anandamide with synthetic standards (Fig. 1). ANOVA revealed time-dependent changes in 2-AG levels derived from lumbar spinal cord extracts of shocked rats relative to non-shocked rats [$F(4,44) = 21.106$, $P < 0.001$] (Fig. 2a). Post hoc analyses confirmed that 2-AG levels were significantly increased in rats killed at 2 min post shock ($P < 0.001$) and decreased at subsequent time points ($P < 0.05$). By contrast, anandamide levels in the lumbar spinal cords of rats subjected to foot shock did not differ reliably from controls. Planned comparisons failed to reveal a significant elevation in anandamide levels at either 2 min ($P = 0.24$) or 5 min ($P = 0.21$) post shock (Fig. 2a). Foot shock also failed to alter either 2-AG or anandamide levels in tissues derived from the occipital cortex (Fig. 2b), an area enriched in cannabinoid CB₁ receptors but not implicated in SIA. A significant correlation was observed between SIA and post-shock levels of 2-AG ($r = 0.96$,

Fig. 1. 2-AG and anandamide are detected in the lumbar spinal cord. (a,b) Representative LC/MS tracings for selected ions characteristic of (a) endogenous 2-AG (top, mass-to-charge ratio, $m/z = 401.3$, an adduct with Na^+ , $[\text{M} + \text{Na}^+]$) and synthetic [$^2\text{H}_8$]-2-AG (bottom, $m/z = 409.3$) and (b) endogenous anandamide (top, $m/z = 370.3$, $[\text{M} + \text{Na}^+]$) and synthetic [$^2\text{H}_4$]-2-anandamide (bottom, $m/z = 374.3$). Synthetic [$^2\text{H}_8$]-2-AG and synthetic [$^2\text{H}_4$]-2-anandamide were added to the samples as internal standards. The first peak in (a) corresponds to 1(3)-AG, a 2-AG isomer produced during sample preparation, which was summed with 2-AG for quantification purposes.

$P = 0.02$), but not anandamide ($r = 0.763$, $P = 0.237$), in the lumbar spinal cord over the same interval (Fig. 3).

3.2. Assessment of SIA

In all studies, baseline tail-flick latencies did not differ between groups prior to administration of drug or vehicle. Moreover, latencies recorded just prior to foot shock, following injection of either drug or vehicle, did not differ between groups. Post-shock latencies were higher than baseline measures in all studies ($P < 0.0001$), demonstrating that continuous foot shock for 3 min elicited robust antinociception. Fig. 3 shows the temporal correspondence between SIA and foot shock-induced endocannabinoid accumulation in the lumbar spinal cord.

Fig. 2. Foot shock (3 min 0.9 mA) stimulates the formation of 2-AG, but not anandamide, in the lumbar spinal cord. Non-shock (open squares) and post-shock (filled circles) levels of 2-AG and anandamide in lumbar spinal cord samples (a) and samples derived from the occipital cortex (b). Mean $\pm$ S.E.M.; $n = 10$ per group. * $P < 0.05$ compared with non-shock controls (ANOVA, Fisher's PLSD test).

3.3. Pharmacological inactivation of CB_1 receptors

Intrathecal injection of rimonabant (2 nmol or 20 nmol) failed to suppress post-shock tail-flick latencies relative to vehicle-treated controls [$F(2,18) = 0.104$, $P = 0.9017$] (Fig. 4).

3.4. Spinal inhibition of monoacylglycerol lipase (MGL)

Intrathecal administration of the MGL inhibitor URB602 (1 nmol) increased post-shock tail-flick latencies [$F(2,17) = 8.954$, $P < 0.003$] relative to either vehicle controls ($P < 0.002$) or animals receiving URB602 co-administered with rimonabant ($P < 0.004$) (Fig. 5). Rimonabant (2 nmol) blocked the URB602-induced potentiation of stress antinociception. Tail-flick latencies observed in animals receiving URB602 co-administered with rimonabant did not differ from vehicle ($P = 0.7529$).

3.5. Spinal inhibition of fatty-acid amide hydrolase (FAAH)

Intrathecal administration of either URB597 (1 nmol) or AA-5-HT (1 nmol or 200 nmol) increased post-shock tail-flick latencies relative to controls [$F(3,32) = 20.765$, $P < 0.0001$

Fig. 3. Temporal correspondence between endocannabinoid mobilization and SIA. A significant correlation was observed between 2-AG but not anandamide levels in the lumbar spinal cord of rats subjected to the stressor (3 min 0.9 mA). The dashed line shows the pre-shock tail-flick latency and non-shock endocannabinoid level, which were matched to facilitate comparison between groups.

and $F(2,14) = 4.571$, $P < 0.03$, respectively] (Fig. 6). Co-administration of rimonabant (2 nmol) with either AA-5-HT or URB597 blocked the potentiation of SIA induced by each compound ($P < 0.0001$ and $P < 0.04$, respectively). Furthermore, both the high (200 nmol) and low (1 nmol) dose of AA-5-HT increased post-stress tail-flick latencies relative to controls ($P < 0.0001$ for either dose). Post hoc analyses revealed that the 1 nmol dose of AA-5-HT was as effective as the 200 nmol dose in potentiating stress antinociception. Administration of either dose of AA-5-HT enhanced stress antinociception from 9–60 min post foot shock.

4. Discussion

We have previously demonstrated that nonopioid SIA is mediated by mobilization of two endocannabinoids, 2-AG and anandamide, in the midbrain PAG (Hohmann et al., 2005). The present results extend those findings and suggest that endocannabinoid actions at spinal CB_1 receptors modulate SIA. Foot shock stress induced time-dependent changes in the

Fig. 4. Intrathecal administration of the selective CB₁ antagonist rimonabant (Ri; 2 nmol or 20 nmol) does not alter nonopioid SIA relative to vehicle-treated controls.

levels of 2-AG, but not anandamide, in the lumbar spinal cord. However, intrathecal administration of rimonabant failed to attenuate nonopioid SIA. Nonetheless, selective inhibitors of MGL and FAAH, administered via the same route, increased both the magnitude and duration of SIA through a CB₁-dependent mechanism. A parsimonious interpretation of these

Fig. 5. Intrathecal administration of the monoacylglycerol lipase (MGL) inhibitor URB602 (1 nmol) enhances nonopioid SIA via a CB₁-dependent mechanism. URB602-induced increases in post-shock tail-flick latencies were blocked by co-administration of rimonabant (2 nmol). Inset: Overall drug effect for the observation interval ($P < 0.0001$) is shown. The dotted line indicates basal nociceptive threshold. Mean $\pm$ S.E.M. * $P < 0.05$ versus other groups (ANOVA, Fisher's PLSD test).

Fig. 6. Intrathecal administration of inhibitors of fatty-acid amide hydrolase (FAAH) enhances nonopioid SIA via a CB₁-dependent mechanism. (a) URB597 (1 nmol) and (b) AA-5-HT (1 nmol or 200 nmol) increase post-shock response latencies in the tail-flick test ($P < 0.0001$ for each study). Rimonabant (2 nmol) blocked these effects. Insets: Overall drug effects for the observation intervals ($P < 0.0001$ for each drug) are shown. The dotted line indicates the basal nociceptive threshold. Mean $\pm$ S.E.M. * $P < 0.05$ versus other groups (ANOVA, Fisher's PLSD test).

findings is that inhibition of MGL or FAAH prevented the deactivation of spinal 2-AG and anandamide, respectively, magnifying nonopioid SIA. Thus, our findings suggest that spinal endocannabinoids regulate, but do not mediate, nonopioid SIA.

It is possible that the placement of chronic indwelling intrathecal catheters elevated anandamide levels in the behavioral studies, and that this change in endocannabinoid tone was augmented by the FAAH inhibitors. However, changes in endocannabinoid tone due to catheter placement appear unlikely because intrathecal rimonabant administration did not alter tail-flick latencies in the presence or absence of foot shock. Moreover, Fos immunocytochemical studies suggest that spinal compression induced by catheter placement does not induce appreciable neuronal activation (Hohmann et al., 1999b).

Electrophysiological studies have provided evidence both for (Chapman, 1999) and against (Harris et al., 2000; Morisset and Urban, 2001) the existence of a tonic endocannabinoid tone at the spinal level. However, in our study, intrathecal rimonabant administration failed to suppress either basal nociceptive thresholds (determined immediately prior to the foot shock) or nonopioid SIA. Hyperalgesic effects of spinal rimonabant (Richardson et al., 1997) may reflect sensitivity of supraspinally-organized (i.e. hot plate) relative to spinally organized (e.g. tail-flick) pain behaviors in measuring lowered nociceptive thresholds. It is also possible that exposure to uncontrolled stress (e.g. due to handling) mobilizes endocannabinoids in behavioral studies (Patel et al., 2005), thereby resulting in a CB₁-dependent apparent hyperalgesia.

Although high doses of anandamide activate transient receptor potential vanilloid 1 (TRPV1) (for review, see van der Stelt and Di Marzo, 2005), several observations suggest that this mechanism is not responsible for the enhancements of SIA observed here. First, systemic administration of the TRPV1 antagonist capsazepine, at a dose that completely blocks capsaicin-induced antinociception, does not alter non-opioid SIA in our paradigm (Suplita et al., *in press*). Second, CB₁ and TRPV1 show minimal colocalization at the axonal level in the spinal cord, with CB₁ localized predominantly to laminae I and II interneurons (Farquhar-Smith et al., 2000) and TRPV1 localized primarily to nociceptive primary afferent terminals (Caterina et al., 1997; Caterina and Julius, 2001). Third, anandamide activation of CB₁ and TRPV1 typically induces opposing effects with distinct time courses (see De Petrocellis and Di Marzo, 2005). However, we observed only enhancements—not attenuation—of SIA following intrathecal administration of FAAH inhibitors and no change in SIA following antagonist treatment. Fourth, rimonabant completely blocked the potentiation of SIA induced by intrathecal administration of inhibitors of MGL or FAAH, at doses that were insufficient to reverse SIA when administered alone. Together, these observations suggest that anandamide acts through CB₁ rather than TRPV1 at the spinal level to modulate SIA.

The foot shock-induced increases in 2-AG levels were smaller than those observed previously in the dorsal midbrain of the same subjects (Hohmann et al., 2005). This observation is consistent with the inability of spinally administered rimonabant to block nonopioid SIA. By contrast, a tenfold lower dose of rimonabant produced a robust suppression of SIA when microinjected into the dorsolateral PAG. Our results collectively suggest that supraspinal sites of action play a pivotal role in endocannabinoid-mediated SIA.

Our data suggest that spinal inhibition of MGL prolongs the duration of action of 2-AG, thereby enhancing endocannabinoid tone at spinal CB₁ receptors to magnify SIA. This enhancement occurred in the absence of reliable changes in spinal anandamide levels. Thus, the antinociceptive effects of MGL inhibitors are not dependent upon concurrent elevations in anandamide that were induced in the midbrain PAG following exposure to the same stressor (Hohmann et al., 2005).

Spinal inhibition of FAAH also potentiated SIA via a CB₁-dependent mechanism. However, foot shock did not reliably increase spinal anandamide levels. Our failure to observe enhancements in anandamide accumulation may reflect lower absolute levels of anandamide relative to 2-AG and consequently higher variability in these measurements. Our data are consistent with the ability of FAAH inhibitors to selectively enhance accumulation of anandamide, but not 2-AG (Cravatt et al., 2001; Lichtman et al., 2002; Kathuria et al., 2003; Fegley et al., 2005). FAAH may regulate both the distance endocannabinoids diffuse to engage CB₁ receptors and the duration of endocannabinoid actions (Egertová et al., 2003) to increase accumulation of tonically released anandamide. It is also possible that the extent of on-demand anandamide synthesis may be underestimated in the present work due to the rapid metabolism of this lipid by FAAH. Mapping the distribution of MGL, FAAH and CB₁ in the spinal cord could further elucidate the anatomical and functional relationship between cells that degrade 2-AG and those expressing CB₁.

Cannabinoid receptor agonists such as Δ^9 -tetrahydrocannabinol (THC) have limited therapeutic applications at present, mainly because of their undesirable psychoactive effects. However, pharmacological agents that protect endocannabinoids such as 2-AG and anandamide from inactivation may lead to a more circumscribed spectrum of physiological responses than those produced by direct cannabinoid agonists. Ideally, this strategy would enhance endocannabinoid activity only at sites with on-going biosynthesis and release, thereby averting undesirable side effects. The possible use of drugs that inhibit endocannabinoid hydrolysis to treat pain in humans has thus propagated both hope and concern (Cravatt and Lichtman, 2003). FAAH is widely distributed throughout the body (Deutsch and Chin, 1993; Cravatt et al., 1996; Matsuda et al., 1997; Watanabe et al., 1998; Maccarrone et al., 2000) and implicated in the metabolism of a variety of anandamide analogues (Desarnaud et al., 1995; Cravatt et al., 1996; Bisogno et al., 1997; Lang et al., 1999a,b; Tiger et al., 2000). Our data demonstrate that local enhancements of endocannabinoid actions at the spinal level are sufficient to potentiate SIA. Additional experiments will be necessary to determine whether inhibitors of endocannabinoid degradation may find therapeutic applications in the treatment of pain and stress-related disorders.

Acknowledgments

The authors would like to thank Nathan Bolton for technical assistance. This work was Supported by DA14022, DA14265 (to A.G.H.) and DA12447, DA3412 (to D.P.).

References

- Akil, H., Young, E., Walker, J.M., Watson, S.J., 1986. The many possible roles of opioids and related peptides in stress-induced analgesia. *Ann. N.Y. Acad. Sci.* 467, 140–153.

- Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L., Di Marzo, V., 1997. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. *J. Biol. Chem.* 272, 3315–3323.
- Bisogno, T., Melck, D., De Petrocellis, L., Bobrov, M., Gretskey, N.M., Bezuglov, V.V., Sitachitta, N., Gerwick, W.H., Di Marzo, V., 1998. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. *Biochem. Biophys. Res. Commun.* 248, 515–522.
- Caterina, M.J., Julius, D., 2001. The vanilloid receptor: a molecular gateway to the pain pathway. *Annu. Rev. Neurosci.* 24, 487–517.
- Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., Julius, D., 1997. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 389, 816–824.
- Chapman, V., 1999. The cannabinoid CB₁ receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. *Br. J. Pharmacol.* 127, 1765–1767.
- Cravatt, B.F., Lichtman, A.H., 2003. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. *Curr. Opin. Chem. Biol.* 7, 469–475.
- Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B., 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* 384, 83–87.
- Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., Lichtman, A.H., 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc. Natl. Acad. Sci. USA* 98, 9371–9376.
- D'Amour, F.E., Smith, D.L., 1941. A method for determining loss of pain sensation. *Pharmacol. Exp. Ther.* 72, 74–79.
- De Petrocellis, L., Di Marzo, V., 2005. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. *Life Sci.* 77, 1651–1666.
- Desarnaud, F., Cadas, H., Piomelli, D., 1995. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. *J. Biol. Chem.* 270, 6030–6035.
- Deutsch, D.G., Chin, S.A., 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. *Biochem. Pharmacol.* 46, 791–796.
- Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Kathuria, S., Piomelli, D., 2002a. Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc. Natl. Acad. Sci. USA* 99, 10819–10824.
- Dinh, T.P., Freund, T.F., Piomelli, D., 2002b. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. *Chem. Phys. Lipids* 121, 149–158.
- Dinh, T.P., Kathuria, S., Piomelli, D., 2004. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol. Pharmacol.* 66, 1260–1264.
- Drew, L.J., Harris, J., Millns, P.J., Kendall, D.A., Chapman, V., 2000. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [³⁵S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. *Eur. J. Neurosci.* 12, 2079–2086.
- Egertová, M., Cravatt, B.F., Elphick, M.R., 2003. Comparative analysis of fatty acid amide hydrolase and CB₁ cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. *Neuroscience* 119, 481–496.
- Farquhar-Smith, W.P., Egertová, M., Bradbury, E.J., McMahon, S.B., Rice, A.S., Elphick, M.R., 2000. Cannabinoid CB₁ receptor expression in rat spinal cord. *Mol. Cell Neurosci.* 15, 510–521.
- Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Piomelli, D., 2005. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. *J. Pharmacol. Exp. Ther.* 313, 352–358.
- Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M., Piomelli, D., 1999. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat. Neurosci.* 2, 358–363.
- Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., Hipkin, R.W., 2000. Endocannabinoid 2-arachidonoyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol. Pharmacol.* 57, 1045–1050.
- Harris, J., Drew, L.J., Chapman, V., 2000. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. *Neuroreport* 11, 2817–2819.
- Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C., 1991. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J. Neurosci.* 11, 563–583.
- Hohmann, A.G., Suplita, R.L., 2004. Cannabinoid mechanisms of pain modulation: supraspinal sites of cannabinoid analgesic action. In: Wenger, T. (Ed.), *Recent Advances in the Pharmacology and Physiology of Cannabinoids*. Research Signpost, Kerala, India.
- Hohmann, A.G., Tsou, K., Walker, J.M., 1998. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. *Neurosci. Lett.* 257, 119–122.
- Hohmann, A.G., Briley, E.M., Herkenham, M., 1999a. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. *Brain Res.* 822, 17–25.
- Hohmann, A.G., Tsou, K., Walker, J.M., 1999b. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. *J. Neurophysiol.* 81, 575–583.
- Hohmann, A.G., Tsou, K., Walker, J.M., 1999c. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. *Acta Pharmacol. Sin.* 20, 1132–1136.
- Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., Krey, J.F., Walker, J.M., Holmes, P.V., Crystal, J.D., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Piomelli, D., 2005. An endocannabinoid mechanism for stress-induced analgesia. *Nature* 435, 1108–1112.
- Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., Piomelli, D., 2003. Modulation of anxiety through blockade of anandamide hydrolysis. *Nat. Med.* 9, 76–81.
- Kelly, S., Chapman, V., 2001. Selective cannabinoid CB₁ receptor activation inhibits spinal nociceptive transmission in vivo. *J. Neurophysiol.* 86, 3061–3064.
- Lang, W., Qin, C., Lin, S., Khanolkar, A.D., Goutopoulos, A., Fan, P., Abouzid, K., Meng, Z., Biegel, D., Makriyannis, A., 1999. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. *J. Med. Chem.* 42, 896–902.
- Lewis, J.W., Cannon, J.T., Liebeskind, J.C., 1980a. Opioid and nonopioid mechanisms of stress analgesia. *Science* 208, 623–625.
- Lewis, J.W., Cannon, J.T., Stapleton, J.M., Liebeskind, J.C., 1980b. Stress activates endogenous pain-inhibitory systems: opioid and non-opioid mechanisms. *Proc. West Pharmacol. Soc.* 23, 85–88.
- Lichtman, A.H., Martin, B.R., 1991. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. *Brain Res.* 559, 309–314.
- Lichtman, A.H., Cook, S.A., Martin, B.R., 1996. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. *J. Pharmacol. Exp. Ther.* 276, 585–593.
- Lichtman, A.H., Hawkins, E.G., Griffin, G., Cravatt, B.F., 2002. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. *J. Pharmacol. Exp. Ther.* 302, 73–79.
- Maccarrone, M., Fiorucci, L., Erba, F., Bari, M., Finazzi-Agro, A., Ascoli, F., 2000. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. *FEBS Lett.* 468, 176–180.
- Martin, W.J., Patrick, S.L., Coffin, P.O., Tsou, K., Walker, J.M., 1995. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. *Life Sci.* 56, 2103–2109.
- Martin, W.J., Loo, C.M., Basbaum, A.I., 1999. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. *Pain* 82, 199–205.

- Matsuda, S., Kanemitsu, N., Nakamura, A., Mimura, Y., Ueda, N., Kurahashi, Y., Yamamoto, S., 1997. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. *Exp. Eye Res.* 64, 707–711.
- Meng, I.D., Manning, B.H., Martin, W.J., Fields, H.L., 1998. An analgesia circuit activated by cannabinoids. *Nature* 395, 381–383.
- Morisset, V., Urban, L., 2001. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. *J. Neurophysiol.* 86, 40–48.
- Patel, S., Roelke, C.T., Rademacher, D.J., Hillard, C.J., 2005. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. *Eur. J. Neurosci.* 21, 1057–1069.
- Piomelli, D., 2003. The molecular logic of endocannabinoid signalling. *Nat. Rev. Neurosci.* 4, 873–884.
- Richardson, J.D., Aanonsen, L., Hargreaves, K.M., 1997. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. *Eur. J. Pharmacol.* 319, R3–R4.
- Richardson, J.D., Aanonsen, L., Hargreaves, K.M., 1998. Antihyperalgesic effects of spinal cannabinoids. *Eur. J. Pharmacol.* 345, 145–153.
- Savinainen, J.R., Jarvinen, T., Laine, K., Laitinen, J.T., 2001. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB₁ receptor-dependent G-protein activation in rat cerebellar membranes. *Br. J. Pharmacol.* 134, 664–672.
- Smith, P.B., Martin, B.R., 1992. Spinal mechanisms of delta Δ^9 -tetrahydrocannabinol-induced analgesia. *Brain Res.* 578, 8–12.
- Stella, N., Schweitzer, P., Piomelli, D., 1997. A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388, 773–778.
- Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., Waku, K., 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem. Biophys. Res. Commun.* 215, 89–97.
- Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., Ishima, Y., 1999. Evidence that the cannabinoid CB₁ receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. *J. Biol. Chem.* 274, 2794–2801.
- Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., Waku, K., 2000. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB₂ receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. *J. Biol. Chem.* 275, 605–612.
- Suplita, R.L., Gutierrez, T., Farthing, J.N., Hohmann, A.G. Inhibition of fatty acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites-of-action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. *Neuropharmacology*, in press, doi: 10.1016/j.neuropharm.2005.07.007.
- Tiger, G., Stenstrom, A., Fowler, C.J., 2000. Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate. *Biochem. Pharmacol.* 59, 647–653.
- Tsou, K., Brown, S., Sañudo-Pena, M.C., Mackie, K., Walker, J.M., 1998a. Immunohistochemical distribution of cannabinoid CB₁ receptors in the rat central nervous system. *Neuroscience* 83, 393–411.
- Tsou, K., Nogueron, M.I., Muthian, S., Sañudo-Pena, M.C., Hillard, C.J., Deutsch, D.G., Walker, J.M., 1998b. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. *Neurosci. Lett.* 254, 137–140.
- van der Stelt, M., Di Marzo, V., 2005. Anandamide as an intracellular messenger regulating ion channel activity. *Prostaglandins and Other Lipid Mediators* 77, 111–122.
- Vaughan, C.W., Connor, M., Bagley, E.E., Christie, M.J., 2000. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. *Mol. Pharmacol.* 57, 288–295.
- Watanabe, K., Ogi, H., Nakamura, S., Kayano, Y., Matsunaga, T., Yoshimura, H., Yamamoto, I., 1998. Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. *Life Sci.* 62, 1223–1229.
- Welch, S.P., Stevens, D.L., 1992. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. *J. Pharmacol. Exp. Ther.* 262, 10–18.
- Welch, S.P., Thomas, C., Patrick, G.S., 1995. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. *J. Pharmacol. Exp. Ther.* 272, 310–321.
- Yaksh, T.L., 1981. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. *J. Clin. Pharmacol.* 21, 334S–340S.
- Yaksh, T.L., Rudy, T.A., 1976. Chronic catheterization of the spinal subarachnoid space. *Physiol. Behav.* 17, 1031–1036.
- Zimmermann, M., 1983. Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 16, 109–110.